Nitrogen Attached Directly Or Indirectly To The Ring Nitrogen Of The Seven-membered Hetero Ring By Acyclic Nonionic Bonding (e.g., Diltiazem, Etc.) Patents (Class 514/211.07)
  • Patent number: 10143694
    Abstract: A method for healing a hard-to-heal wound including the steps of: topically administering a wound healing composition to a wounded area, wherein the wound healing composition includes, at least one of: (a) a medicament characterized as a calcium channel blocker or pharmaceutically acceptable salts or solvates thereof; (b) a medicament characterized as an alpha-adrenergic antagonist or pharmaceutically acceptable salts or solvates thereof; (c) a medicament characterized as a direct vasodilator or pharmaceutically acceptable salts or solvates thereof; and (d) a medicament characterized as a phosphodiesterase type five inhibitor or pharmaceutically acceptable salts or solvates thereof; and (e) a hemorrheologic agent or pharmaceutically acceptable salts or solvates thereof; (f) a primary dermal penetrating agent or pharmaceutically acceptable salts or solvates thereof: and (g) a topical stimulating agent or pharmaceutically acceptable salts or solvates thereof.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: December 4, 2018
    Inventors: Matthew H. Kopacki, Michael J. Torsiello
  • Patent number: 9901627
    Abstract: A composition of botulinum toxin is claimed which can penetrate into the ocular surface inclusive of a penetration through a conjunctiva, cornea, and other structures. This composition allows for a maximal penetration of a topical preparation of botulinum toxin which serves to reduce the need for frequent allergy drops for the treatment of ocular surface disease and other conditions causing ocular surface inflammation or deep ocular inflammation. No puncture of the needle is necessary for the administration. Herein describes a novel composition using several principles based on composition, method of application, which enhances the effectiveness of the penetration.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: February 27, 2018
    Assignee: Revance Therapeutics, Inc.
    Inventor: Gary E. Borodic
  • Patent number: 9700549
    Abstract: Methods are provided for treating conditions including chronic pelvic pain, in which there are palpable trigger points of local areas of muscle restriction and spasticity that recreate or refer pain of patients complaints upon palpation, chronic pelvic pain syndrome, pelvic floor myalgia, pelvic floor dysfunction, interstitial cystitis, levator ani syndrome, coccygodynia, prostatodynia, piriformis syndrome, anal sphincter pain, bowel movement pain, post bowel movement pain, ejaculatory pain, post ejaculatory pain, sitting pain, post bowel movement pain, rectal pain, tailbone pain, urinary frequency, urinary urgency, urinary hesitancy, post urinary pain, overactive bladder, perineal pain, penile pain, vaginismus, anismus, sexual dysfunction, reduced level of ejaculate or reduced penile erection, myofascial pain in muscle tissue of a patient who has one or more trigger points in the muscle tissue, or the pain/sensitivity of pelvic floor muscle trigger points and specific areas of myofascial restriction detected
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 11, 2017
    Inventor: David Wise
  • Publication number: 20150141404
    Abstract: Disclosed are non-ionic surfactant vesicle formulations of calcium channel blockers, such as diltiazem, and methods of using the formulations for treating anal disorders.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Rajiv Mathur, Nidhi Parikh, Wennan Zhao, Meng Zhou
  • Patent number: 8993558
    Abstract: A composition, use of and a method of removing a hyperplastic skin lesion on a mammal comprising administering to the lesion or locus thereof a therapeutically effective amount of a composition comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof and a pharmaceutically acceptable diluent or carrier.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: March 31, 2015
    Inventor: Kenneth W. Adams
  • Patent number: 8962016
    Abstract: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: February 24, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Saurabh Srivastava, Vinayak Dinkar Kadam, Girish Kumar Jain
  • Publication number: 20150010623
    Abstract: Controlled release preparations and soft capsules are provided. Also provided are emulsions and suspensions, including compositions and methods of manufacturing controlled release soft capsules, where the fill contains a suspension and/or an emulsion.
    Type: Application
    Filed: August 15, 2014
    Publication date: January 8, 2015
    Inventors: EmadEldin M. Hassan, Nachiapan Chidambaram, Aqeel A. Fatmi
  • Publication number: 20150005290
    Abstract: To characterize the urinary exosome miRNome, microarrays were used to identify the miRNA spectrum present within urinary exosomes from ten individuals that were previously classified for their salt sensitivity status. The present application discloses distinct patterns of selected exosomal miRNA expression that were different between salt-sensitive (SS), salt-resistant (SR), and inverse salt-sensitive (ISS) individuals. These miRNAs can be useful as biomarkers either individually or as panels comprising multiple miRNAs. The present invention provides compositions and methods for identifying, diagnosing, monitoring, and treating subjects with salt sensitivity of blood pressure. The applications discloses panels of miRNAs useful for comparing profiles, and in some cases one or more of the miRNAs in a panel can be used. The miRNAs useful for distinguishing SS and SR or ISS and SR subjects. One or more of the 45 miRNAs can be used. Some of the miRNAs have not been previously reported to be circulating.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 1, 2015
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Robin A. Felder, Julia Carlson, John J. Gildea
  • Publication number: 20150005291
    Abstract: Cosmetic skin and hair care compositions for enhancing the growth and appearance of mammalian hair in an individual are provided, which compositions comprise a dose of an L-type calcium channel blocker effective to promote anagen phase of the hair cycle. As shown herein, anagen phase promotion can result in more rapid hair growth.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 1, 2015
    Inventors: Anthony Oro, Ricardo Ei Dolmetsch, Gozde Yucel
  • Publication number: 20140378435
    Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: Board of Regents, University of Texas System
    Inventors: Robert A. Davey, Andrey A. Kolokoltsov, Mohammad F. Saeed
  • Patent number: 8906903
    Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: December 9, 2014
    Assignee: S.L.A. Pharma AG
    Inventors: Michael A. Kamm, Robin K. S. Phillps
  • Publication number: 20140322311
    Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.
    Type: Application
    Filed: July 7, 2014
    Publication date: October 30, 2014
    Applicant: Grünenthal GmbH
    Inventors: Judy Ashworth, Elisabeth Arkenau Maric, Johannes Bartholomäus, Heinrich Kugelmann
  • Publication number: 20140286931
    Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Inventor: Chengzhi Zhang
  • Publication number: 20140242166
    Abstract: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.
    Type: Application
    Filed: March 3, 2014
    Publication date: August 28, 2014
    Applicant: Penwest Pharmaceuticals Co.
    Inventors: Anand R. Baichwal, Troy W McCALL, Lirong LlU, Steve LABUDZINSKI
  • Publication number: 20140234402
    Abstract: Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: SignPath Pharma Inc.
    Inventor: Lawrence Helson
  • Publication number: 20140206632
    Abstract: A method for determining the risk, severity or progression of cardiovascular disease, such as cardiac heart failure. A method for determining the likelihood of admission to the hospital for cardiac heart failure. The methods include determining the concentration of ET-1 and the concentration of one or more of biomarkers selected from the group consisting of cardiac troponin (e.g., cTnI, cTnT), VEGF, BNP, NT-proBNP, and IL-6 in a blood, serum or plasma sample from the patient.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 24, 2014
    Applicant: Singulex, Inc.
    Inventors: John Todd, Joel Estis, Victoria Torres
  • Publication number: 20140199291
    Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.
    Type: Application
    Filed: September 13, 2008
    Publication date: July 17, 2014
    Applicant: Biogen Idec MA Inc
    Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
  • Patent number: 8778395
    Abstract: A controlled release diltiazem dosage formulation comprising a plurality of diltiazem pellets and a gel-forming material where the time of maximum diltiazem blood plasma levels occurs more than 8 hours after administration and preferably more than 10 hours after administration.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: July 15, 2014
    Assignee: Andrx Labs, LLC
    Inventors: Xiu Xiu Cheng, Xiaohong Qi, Guohua Zhang, Manesh Dixit
  • Publication number: 20140148438
    Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 29, 2014
    Inventor: Michael Farber
  • Publication number: 20140079780
    Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: GRUENENTHAL GMBH
    Inventors: Elisabeth ARKENAU MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
  • Publication number: 20130338143
    Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
    Type: Application
    Filed: November 15, 2011
    Publication date: December 19, 2013
    Applicant: Neuroderm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawozink
  • Publication number: 20130296237
    Abstract: The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and/or an inhibitor of cholesterol synthesis or absorption.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Inventors: Michael B. Kastan, Clay F. Semenkovich, Jochen Schneider
  • Publication number: 20130274245
    Abstract: The present invention relates to the prevention of cardiovascular and central nervous system side effects in mammals who receive transfusions of hemoglobin based oxygen carriers (HBOC) or stored blood products containing a concentration of hemoglobin sufficient to induce vasoconstriction, by adding a vasoactivity reducing effective amount of one or more phosphodiesterase inhibitors in combination with a calcium channel blocker and/or an alpha agonist, to the circulation, or alternatively to the HBOC or stored blood, thereby preventing the manifestation of vasoactivity attributable to the presence of free tetrameric hemoglobin (Hb).
    Type: Application
    Filed: March 12, 2013
    Publication date: October 17, 2013
    Inventor: Jan BLUMENSTEIN
  • Publication number: 20130274235
    Abstract: Provided herein are methods and compositions for the treatment of motor neuron diseases including, for example, amyotrophic lateral sclerosis. Suitable therapeutic agents include, for example, agents that up-regulate the expression IGF-II or guanine deaminase in a cell.
    Type: Application
    Filed: October 10, 2011
    Publication date: October 17, 2013
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ole Isacson, Anna Charlotta Teresia Magnuson Osborn
  • Patent number: 8557865
    Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: October 15, 2013
    Assignee: Calosyn Pharma, Inc.
    Inventor: David D. Waddell
  • Publication number: 20130216625
    Abstract: The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily dosage in a range of from about 5 mg to about 1500 mg. The invention furthermore relates to a method of treating insulin resistance or diseases associated with insulin resistance in a mammal, said method comprises administering to said mamma, preferably a human subject, a substance with the core structure of formula (I), preferably in a daily dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples of diseases associated with insulin resistance and e.g.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 22, 2013
    Applicant: STEVIA APS
    Inventors: Kjeld Hermansen, Per Bendix Jeppesen
  • Patent number: 8501727
    Abstract: The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: August 6, 2013
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Dominik Herbart, Harry J. Leighton
  • Publication number: 20130183289
    Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.
    Type: Application
    Filed: September 13, 2008
    Publication date: July 18, 2013
    Applicant: Biogen Idec MA Inc
    Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
  • Publication number: 20130178463
    Abstract: A buccal delivery system is disclosed suitable for delivery of a therapeutic agent to the oral cavity of a patient. The delivery system comprises a matrix for containing and releasing the therapeutic agent into the oral cavity and an alkyl N,N-disubstituted amino acetate in said matrix. A particularly preferred delivery system comprises a matrix containing an effective amount of therapeutic agent together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate salt.
    Type: Application
    Filed: September 23, 2011
    Publication date: July 11, 2013
    Applicants: Rutgers, The State University of New Jersey, Nexmed Holdings, Inc.
    Inventors: Bassam B. Damaj, Richard Martin, Bozena Michniak-Kohn, Long-Sheng Hu
  • Patent number: 8476259
    Abstract: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 2, 2013
    Assignee: Asahi Kasei Pharma Corporation
    Inventor: Benson Fong
  • Publication number: 20130084325
    Abstract: The invention provides a method of manufacturing a patch preparation comprising (a) pouring a composition for forming an adhesive layer into a container having a concave part with a shape corresponding to a patch preparation to be manufactured, wherein the composition contains a drug, an adhesive polymer, and an organic solvent; (b) removing the organic solvent from the composition through drying to form a drug-containing adhesive layer in the concave part; and (c) laminating a support on the drug-containing adhesive layer to provide the patch preparation comprising a support and the drug-containing adhesive layer formed on one surface of the support.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 4, 2013
    Applicant: NITTO DENKO CORPORATION
    Inventor: Nitto Denko Corporation
  • Publication number: 20130079332
    Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.
    Type: Application
    Filed: November 26, 2012
    Publication date: March 28, 2013
    Inventors: MICHAEL A. KAMM, ROBIN K.S. PHILLPS
  • Publication number: 20130022660
    Abstract: The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.
    Type: Application
    Filed: July 22, 2012
    Publication date: January 24, 2013
    Applicant: EDGE THERAPEUTICS, INC.
    Inventors: R. Loch Macdonald, Brian A. Leuthner
  • Publication number: 20130012479
    Abstract: The present invention relates to new crystalline polymorphs of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride, processes for their preparation and their use, in particular for the preparation of medicaments.
    Type: Application
    Filed: June 27, 2012
    Publication date: January 10, 2013
    Applicant: SANOFI
    Inventors: Norbert NAGEL, Bruno BAUMGARTNER, Harald BERCHTOLD, Oliver PLETTENBURG, Dieter KADEREIT, Mandy MOHNICKE, Simon GESSLER, Joachim TILLNER
  • Patent number: 8329746
    Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: December 11, 2012
    Assignee: CaloSyn Pharma, Inc.
    Inventor: David D. Waddell
  • Publication number: 20120309709
    Abstract: A composition and method for the treatment of degenerative joint disease is disclosed. The composition includes a combination of a first ion-channel regulator, at least a second ion-channel regulator, and a pharmaceutically acceptable carrier suitable for intraarticular injection. Methods and kits for treating a degenerative joint disease are also disclosed.
    Type: Application
    Filed: February 8, 2012
    Publication date: December 6, 2012
    Inventors: David D. Waddell, Andrew A. Marino, Oleg V. Kolomytkin
  • Patent number: 8318721
    Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: November 27, 2012
    Assignee: S.L.A. Pharma AG
    Inventors: Michael A. Kamm, Robin K. S. Phillips
  • Publication number: 20120245145
    Abstract: In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA synthesis processing of viral protein translation, transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier; and/or is caused by damage to the animal/mammal by a pathological immune response to antigens.
    Type: Application
    Filed: December 3, 2010
    Publication date: September 27, 2012
    Inventor: Kenneth W. Adams
  • Publication number: 20120237590
    Abstract: Compositions and methods for treating type 2 diabetes and its sequelae by intravenous or subcutaneous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly one or more anti-diabetic agents to human subjects are disclosed herein. The composition of the present invention may be used to: (i) treat patients with diabetes in advanced stages with evidence of any or all encephalopathy, retinopathy, nephropathy, pancreatitis or neoplasias; (ii) treat patients with diabetic disease status without symptomatic or pathologic evidence of associated sequelae but requiring better glycemic control than that offered by standard of care anti-diabetic; and (iii) patients with objective signs or symptoms of sequelae from diabetes of anti-diabetic drugs. One three-drug combination of the present invention includes a slow release PLGA-curcumin and an oral gliptin (DPP-4)-inhibitor or any incretin-mimetic and metformin.
    Type: Application
    Filed: March 15, 2012
    Publication date: September 20, 2012
    Applicant: SIGNPATH PHARMA INC.
    Inventor: Lawrence Helson
  • Publication number: 20120122845
    Abstract: A method for the preparation of a bioadhesive compact matrix, which comprises the preparation of a uniform mixture of powders comprising one alkylcellulose or one hydroxy alkylcellulose and a non-water-soluble, water-swellable cross-linked polycarboxylic polymer; the preparation of compressed units starting from such powder mixture by direct compression and finally the heating of the compressed units thus obtained to a temperature in the range of 80-250° C. for a time of 1-60 minutes; the powder mixture can also comprise at least one active substance and the compressed units thus obtained are characterized by a prolonged release, and have a release kinetics of the active substance substantially of zero order in an aqueous solution at pH 4-8.
    Type: Application
    Filed: September 10, 2009
    Publication date: May 17, 2012
    Inventors: Gabriele Caviglioli, Brunella Parodi, Eleonora Russo, Sergio Cafaggi, Gaetano Bignardi, Paola Cirrincione
  • Publication number: 20120107400
    Abstract: A pH dependent drug delivery system comprising a pH sensitive graft copolymer, a therapeutically active agent and other pharmaceutically acceptable ingredients. More specifically, a composition which is capable of suppressing the drug release in the acidic pH prevalent in the stomach and releasing the drug over an extended period of time at pH prevalent in the intestinal region.
    Type: Application
    Filed: March 5, 2010
    Publication date: May 3, 2012
    Inventors: Ramesh Muthusamy, Mohan Gopalkrishna Kulkarni
  • Publication number: 20120064056
    Abstract: The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical benefit. The present invention teaches administration of DCA with cardioprotective or hemodynamic drugs as an adjunct therapy thereby conferring added clinical benefit to clinically recommended protocols.
    Type: Application
    Filed: November 21, 2011
    Publication date: March 15, 2012
    Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA TEC Edmonton
    Inventors: GARY D. LOPASCHUK, RUTH COLLINS-NAKAI
  • Publication number: 20120021989
    Abstract: The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic 5 methods, uses and procedures for utilizing such susceptibility markers.
    Type: Application
    Filed: March 30, 2010
    Publication date: January 26, 2012
    Applicant: deCODE Genetics ehf.
    Inventors: Hilma Holm, Daniel Gudbjartsson
  • Publication number: 20110319382
    Abstract: A composition, use of and a method of removing a hyperplastic skin lesion on a mammal comprising administering to the lesion or locus thereof a therapeutically effective amount of a composition comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof and a pharmaceutically acceptable diluent or carrier.
    Type: Application
    Filed: October 29, 2009
    Publication date: December 29, 2011
    Inventor: Kenneth W. Adams
  • Publication number: 20110311631
    Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol. The coating layer comprises a polymeric portion consisting of a water-insoluble neutral vinyl polymer or vinyl copolymer and an amino methacrylate copolymer and an excipients portion consisting of a lubricant, an emulsifier, a plasticizer and optionally a cellulosic compound.
    Type: Application
    Filed: March 18, 2009
    Publication date: December 22, 2011
    Applicant: EVONIK RÖHM GMBH
    Inventors: Hans Baer, Thomas Fuerst, Thomas Rupp, Gerhard Renner, Michael Gottschalk
  • Publication number: 20110311628
    Abstract: A pulsatile release composition which releases the content rapidly after a predetermined lag time comprising a drug containing a core, coated with a pH sensitive graft copolymer. The coating suppresses the drug release at acidic pH prevalent in the stomach and releases it either immediately or after a lag time in the intestinal region. Combinations of multiple numbers of coated and uncoated units provide a sequential pulsatile release of same or different therapeutic agents.
    Type: Application
    Filed: March 8, 2010
    Publication date: December 22, 2011
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Ramesh Muthusamy, Mohan Gopalkrishna Kulkarni
  • Publication number: 20110274755
    Abstract: The invention provides a composition and method for treatment of a subject suffering from liver disease comprising the oral administration of a slow release formulation of diltiazem and thiamine.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 10, 2011
    Inventor: Howard J. Smith
  • Patent number: 8048875
    Abstract: Bethanechol, diltiazem, or a combination thereof is administered locally to the anus for the treatment of benign anal disorders, in particular anal fissures and hemorrhoids. The agents induce a reduction in the mean and resting pressure, thereby assisting in the healing of the anal fissures and hemorrhoids.
    Type: Grant
    Filed: February 23, 1997
    Date of Patent: November 1, 2011
    Assignee: S.L.A. Pharma AG
    Inventors: Michael A. Kamm, Robin K. S. Phillips
  • Publication number: 20110263568
    Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.
    Type: Application
    Filed: July 8, 2011
    Publication date: October 27, 2011
    Inventors: MICHAEL A. KAMM, ROBIN K.S. PHILLIPS
  • Publication number: 20110250197
    Abstract: This invention relates to a combination product or medicament comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 13, 2011
    Applicant: RANBAXY LABORATORIES
    Inventors: Jitendra A. SATTIGERI, Vinay S. BANSAL